Skip to content

Pulmonary Rehabilitation of Patients With a History of COVID-19

Impact of Pulmonary Rehabilitation on Quality of Life, Body Composition and Respiratory Function of Patients With a History of COVID-19

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04751617
Enrollment
60
Registered
2021-02-12
Start date
2021-01-01
Completion date
2021-03-31
Last updated
2021-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

SARS-CoV-2, Pulmonary rehabilitation, Quality of life, Body composition, Spirometry, Computed tomography, Morphology, Gasometry

Brief summary

This study will determine the impact of pulmonary rehabilitation on quality of life, body composition and respiratory function in patients with a history of COVID-19.

Detailed description

In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of symptoms, mainly respiratory infection. In March 2020, the World Health Organization (WHO) declared Coronavirus Disease 2019 (COVID-19) a pandemic. COVID-19 has spread rapidly over several months, affecting patients across all age groups and geographic areas. The disease has a diverse course; patients may range from asymptomatic to those with respiratory failure, complicated by acute respiratory distress syndrome. The main objective of this study is to assess the impact of pulmonary rehabilitation on quality of life, body composition and respiratory function in patients with a history of COVID-19. The patients after COVID-19 will be included in the pulmonary rehabilitation protocol. The duration of rehabilitation will depend on the patient's condition: from 7 to 14 days. Measurements: * quality of life (WHOQoL-BREF) * body composition (bioelectrical impedance analysis, BC-420 MA, Tanita) * weight, height and BMI * spirometry (Spirometr PNEUMO, abcMED) * diffusion lung capacity for carbon monoxide (LUNGTEST 1000) * morphology (CRP, D-Dimer, WBC) and gasometry (pCO2, pO2) * chest computed tomography (CT). These parameters will be recorded before the first day of rehabilitation (baseline), after completion of rehabilitation protocol, and three months after completion the rehabilitation protocol. A change in evaluated parameters will be assessed. This will be a prospective, interventional, non-randomized study. All patients will be enrolled by Podkarpackie Center for Lung Diseases in Rzeszów.

Interventions

PROCEDUREPulmonary rehabilitation

Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.

Sponsors

University of Rzeszow
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and female patients treated in Provincial Clinical Hospital No. 1 in Rzeszów/ Podkarpackie Center for Lung Diseases in Rzeszów, * Patients with a history of COVID-19, * Having obtained written informed consent (signed and dated) to participate in the study, * Age at enrollment ≥ 18 years of age, * No contraindications to pulmonary rehabilitation, * No contraindications for body composition testing (bioelectrical impedance analysis).

Exclusion criteria

* Refusal to participate in the study, * Patients with any acute disease in the last 3 months before baseline, * Patients currently enrolled in any clinical trial, * Currently infected patients with COVID-19.

Design outcomes

Primary

MeasureTime frameDescription
Change in the quality of lifeat baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionComparison of the World Health Organization Quality of Life (WHOQOL-BREF) questionnaire mean between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol. The questionnaire consists of 26 questions. Answers are awarded a score in a five-point scale (1-5). Answer scores are calculated according to the WHOQOL-BREF algorithm in the range of 0-100 points. Higher score corresponds to higher quality of life.

Secondary

MeasureTime frameDescription
Change in respiratory flow parameters (spirometry)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the results of: 1. Peak Expiratory Flow (PEF) and 2. Forced Expiratory Flow at 25-75% of vital capacity (FEF 25-75%) between baseline, immediately after the end of rehabilitation protocol, and 3 months after the end of the rehabilitation protocol. To obtain the parameters' values, patients will perform forced inspiration-expiration manoeuvre, and flow-volume loop will be recorded.
Change in lung diffusing capacityat baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the results of Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) \[ml/min/kPa\] between baseline, immediately after the end of rehabilitation protocol, and 3 months after the end of the rehabilitation protocol. To obtain parameter value, patients will perform a full inspiration of a gas mixture containing 0.3% of carbon monoxide; after ten-second breath hold patient exhales and the exhaled breath will be collected and analysed.
Change in Body Mass Index (BMI)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the results of a BMI (kg/m\^2) between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol. To calculate BMI, the body height measurement will be performed at baseline using a stadiometer (unit: meter). Body weight will be measure at baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol (unit: kilogram). BMI will be calculated as body weight (kg) divided by height (m) squared.
Change in the body composition (bioelectrical impedance analysis)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the mean content of body fat (%), fat-free mass (%), total body water (%) and muscle mass (%) between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol. Body composition will be obtained using a bioelectrical impedance analysis (BIA) method by foot-to-foot body composition analyzer.
Change in lung volume parameters (spirometry)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the results of: 1. Forced Expiratory Volume in one second (FEV1), 2. Forced Vital Capacity (FVC), 3. Total Lung Capacity (TLC), and 4. Residual volume (RV) between baseline, immediately after the end of rehabilitation protocol, and 3 months after the end of the rehabilitation protocol. To obtain the parameters' values, patients will perform tidal breathing and forced inspiration-expiration manoeuvre, and flow-volume loop will be recorded.
Change in D-Dimer values (blood sample)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the values of D-Dimer \[ng/mL\] between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol.
Change in white blood cell (WBC) values (blood sample)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the values of white blood cell (WBC) \[count/mm\^3\] between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol.
Change in gasometry (blood sample)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the values of pressures of carbon dioxide (pCO2) \[mm Hg\] and pressures of oxygen (pO2) \[mm Hg\] between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol.
Change in the percentage of opacity (chest computed tomography)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the percentage of opacity (PO%) between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol.
Change in C-reactive protein (CRP) values (blood sample)at baseline, immediately after rehabilitation completion, and 3 months after rehabilitation completionCompare the values of C-reactive protein (CRP) \[mg/dL\] between baseline, immediately after the end of the rehabilitation protocol, and 3 months after the end of the rehabilitation protocol.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026